Opinion: To Realize AI’s Benefits, Don’t Lose Sight of Fundamentals 7/10/2024

Adcomm Votes Unanimously for Lilly’s Alzheimer’s Treatment Donanemab 6/10/2024

Moderna’s COVID-Flu Combo Shot Beats Separate Vaccines in Phase III Study 6/10/2024

Alumis Files for IPO to Fund Phase III Trials of Potential Rival Drug to BMS’ Sotyktu 6/10/2024

Pfizer’s Paxlovid Ineffective Against Long COVID Using 15-Day Regimen: Study 6/10/2024

Skye Nixes Eye Disease Drug After Phase II Failure, Focuses on Metabolic Program 6/10/2024

GSK’s RSV Shot Wins Expanded FDA Approval for At-Risk Adults Aged 50 to 59 6/10/2024

Lilly’s Tirzepatide Improves Liver Fibrosis in Phase II MASH Trial 6/10/2024

Amyloid Remains a Key Target in Next-Generation Alzheimer’s Treatments 6/10/2024

Measuring Muscle Loss in the ‘Wild West’ of Weight Loss Drugs 6/10/2024

Psychedelic Therapies Could Soon Break Through Against Addiction 6/10/2024

Opinion: GenAI Is Not a One-Size-Fits-All Solution for Regulatory Operations 6/10/2024

Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine 5/10/2024

Cell and Gene Therapies Still Have Long Way to Go in Fulfilling Promise 5/10/2024

Five Deaths in Prostate Cancer Trial Send MacroGenics’ Stock Plummeting 5/10/2024

Bluebird Boasts Nearly 140% Revenue Jump, Still Misses Target 5/10/2024

Verona Secures Up To $650M in Funding as it Gears Up for Potential COPD Approval and Launch 5/10/2024

Royalty Pharma Drops $525M for Royalties and Milestones on Sanofi-Licensed MS Therapy 5/10/2024

ASGCT24: Translational Research Powering Potentially Transformative Therapies 5/10/2024

ASGCT24: Early Trial Results from Freeline, Rocket, Creyon and More 5/10/2024